OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S. Virgo, R. Bryan Rumble, Ronald de Wit, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 11, pp. 1274-1305
Open Access | Times Cited: 90
Katherine S. Virgo, R. Bryan Rumble, Ronald de Wit, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 11, pp. 1274-1305
Open Access | Times Cited: 90
Showing 1-25 of 90 citing articles:
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Maha Hussain, Bertrand Tombal, Fred Saad, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 20, pp. 3595-3607
Open Access | Times Cited: 123
Maha Hussain, Bertrand Tombal, Fred Saad, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 20, pp. 3595-3607
Open Access | Times Cited: 123
TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling
Xingkang Jiang, Shanqi Guo, Mengyao Xu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 72
Xingkang Jiang, Shanqi Guo, Mengyao Xu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 72
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification
Neal D. Shore, Judd W. Moul, Kenneth J. Pienta, et al.
Prostate Cancer and Prostatic Diseases (2023) Vol. 27, Iss. 2, pp. 192-201
Open Access | Times Cited: 43
Neal D. Shore, Judd W. Moul, Kenneth J. Pienta, et al.
Prostate Cancer and Prostatic Diseases (2023) Vol. 27, Iss. 2, pp. 192-201
Open Access | Times Cited: 43
Best Approaches and Updates for Prostate Cancer Biochemical Recurrence
Nicholas I. Simon, Chris Parker, Thomas A. Hope, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 352-359
Open Access | Times Cited: 44
Nicholas I. Simon, Chris Parker, Thomas A. Hope, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 352-359
Open Access | Times Cited: 44
PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications
Atish D. Choudhury
The Prostate (2022) Vol. 82, Iss. S1
Open Access | Times Cited: 42
Atish D. Choudhury
The Prostate (2022) Vol. 82, Iss. S1
Open Access | Times Cited: 42
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S. Virgo, R. Bryan Rumble, James A. Talcott
Journal of Clinical Oncology (2023) Vol. 41, Iss. 20, pp. 3652-3656
Closed Access | Times Cited: 27
Katherine S. Virgo, R. Bryan Rumble, James A. Talcott
Journal of Clinical Oncology (2023) Vol. 41, Iss. 20, pp. 3652-3656
Closed Access | Times Cited: 27
Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
Pedro Barata, Andrea Leith, Amanda Ribbands, et al.
The Oncologist (2023) Vol. 28, Iss. 9, pp. 780-789
Open Access | Times Cited: 25
Pedro Barata, Andrea Leith, Amanda Ribbands, et al.
The Oncologist (2023) Vol. 28, Iss. 9, pp. 780-789
Open Access | Times Cited: 25
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Rahul Aggarwal, Glenn Heller, David W. Hillman, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 10, pp. 1114-1123
Closed Access | Times Cited: 13
Rahul Aggarwal, Glenn Heller, David W. Hillman, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 10, pp. 1114-1123
Closed Access | Times Cited: 13
Development of AI-generated medical responses using the ChatGPT for cancer patients
Jae Wook Lee, In-Sang Yoo, Jihye Kim, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 254, pp. 108302-108302
Open Access | Times Cited: 9
Jae Wook Lee, In-Sang Yoo, Jihye Kim, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 254, pp. 108302-108302
Open Access | Times Cited: 9
The Current Therapeutic Landscape for Metastatic Prostate Cancer
A. Gómez Bernal, Alivia Bechler, Kabhilan Mohan, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 351-351
Open Access | Times Cited: 8
A. Gómez Bernal, Alivia Bechler, Kabhilan Mohan, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 351-351
Open Access | Times Cited: 8
Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
Stephen J. Freedland, Rickard Sandin, Janvi Sah, et al.
Cancer Medicine (2021) Vol. 10, Iss. 23, pp. 8570-8580
Open Access | Times Cited: 43
Stephen J. Freedland, Rickard Sandin, Janvi Sah, et al.
Cancer Medicine (2021) Vol. 10, Iss. 23, pp. 8570-8580
Open Access | Times Cited: 43
Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Soumyajit Roy, Rashid K. Sayyid, Fred Saad, et al.
European Urology Oncology (2022) Vol. 5, Iss. 5, pp. 494-502
Closed Access | Times Cited: 31
Soumyajit Roy, Rashid K. Sayyid, Fred Saad, et al.
European Urology Oncology (2022) Vol. 5, Iss. 5, pp. 494-502
Closed Access | Times Cited: 31
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer
Kelly McCann, Shari Goldfarb, Tiffany A. Traina, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7
Kelly McCann, Shari Goldfarb, Tiffany A. Traina, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7
A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions
Parissa Alerasool, Susu Zhou, Eric J Miller, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 147-147
Open Access
Parissa Alerasool, Susu Zhou, Eric J Miller, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 147-147
Open Access
Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS)
Hatice Bölek, Satı Coşkun Yazgan, Furkan Ceylan, et al.
European Journal of Cancer (2025) Vol. 217, pp. 115226-115226
Closed Access
Hatice Bölek, Satı Coşkun Yazgan, Furkan Ceylan, et al.
European Journal of Cancer (2025) Vol. 217, pp. 115226-115226
Closed Access
Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023
Amit D. Raval, Orsolya Lunacsek, Matthew J. Korn, et al.
JCO Oncology Practice (2025)
Closed Access
Amit D. Raval, Orsolya Lunacsek, Matthew J. Korn, et al.
JCO Oncology Practice (2025)
Closed Access
Consenso multidisciplinar sobre idoneidad farmacológica en cáncer de próstata hormono-sensible metastásico
Ángel Borque‐Fernando, Miguel Ángel Calleja‐Hernández, J.M. Cózar-Olmo, et al.
Actas Urológicas Españolas (2023) Vol. 47, Iss. 2, pp. 111-126
Closed Access | Times Cited: 12
Ángel Borque‐Fernando, Miguel Ángel Calleja‐Hernández, J.M. Cózar-Olmo, et al.
Actas Urológicas Españolas (2023) Vol. 47, Iss. 2, pp. 111-126
Closed Access | Times Cited: 12
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study
Ronald Tutrone, Fred Saad, Daniel J. George, et al.
European Urology Oncology (2023) Vol. 7, Iss. 4, pp. 906-913
Open Access | Times Cited: 11
Ronald Tutrone, Fred Saad, Daniel J. George, et al.
European Urology Oncology (2023) Vol. 7, Iss. 4, pp. 906-913
Open Access | Times Cited: 11
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1
E. David Crawford, Alan H. Bryce, Maha Hussain, et al.
JU Open Plus (2024) Vol. 2, Iss. 4
Open Access | Times Cited: 4
E. David Crawford, Alan H. Bryce, Maha Hussain, et al.
JU Open Plus (2024) Vol. 2, Iss. 4
Open Access | Times Cited: 4
Real-World Treatment Patterns and Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights From a Retrospective Cohort Study
Emad Tashkandi
Cancer Management and Research (2025) Vol. Volume 17, pp. 419-428
Open Access
Emad Tashkandi
Cancer Management and Research (2025) Vol. Volume 17, pp. 419-428
Open Access
KEYNOTE-991: Pembrolizumab Plus Enzalutamide and Androgen Deprivation for Metastatic Hormone-Sensitive Prostate Cancer
Christian Gratzke, Mariusz Kwiatkowski, Ugo De Giorgi, et al.
Future Oncology (2022) Vol. 18, Iss. 37, pp. 4079-4087
Open Access | Times Cited: 17
Christian Gratzke, Mariusz Kwiatkowski, Ugo De Giorgi, et al.
Future Oncology (2022) Vol. 18, Iss. 37, pp. 4079-4087
Open Access | Times Cited: 17
Utilization of genetic testing in men with advanced prostate cancer
Jonathan Aguiar, Eric V. Li, Mohammad R. Siddiqui, et al.
The Prostate (2023) Vol. 83, Iss. 6, pp. 516-523
Closed Access | Times Cited: 9
Jonathan Aguiar, Eric V. Li, Mohammad R. Siddiqui, et al.
The Prostate (2023) Vol. 83, Iss. 6, pp. 516-523
Closed Access | Times Cited: 9
Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer
Choon Ta Ng, Hilda M. Gonzalez Bonilla, Alan H. Bryce, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 8, pp. 889-899
Closed Access | Times Cited: 9
Choon Ta Ng, Hilda M. Gonzalez Bonilla, Alan H. Bryce, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 8, pp. 889-899
Closed Access | Times Cited: 9
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer
Rachel Glicksman, Matthew Ramotar, Ur Metser, et al.
International Journal of Radiation Oncology*Biology*Physics (2022) Vol. 114, Iss. 4, pp. 693-704
Closed Access | Times Cited: 15
Rachel Glicksman, Matthew Ramotar, Ur Metser, et al.
International Journal of Radiation Oncology*Biology*Physics (2022) Vol. 114, Iss. 4, pp. 693-704
Closed Access | Times Cited: 15
Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials
Junlong Zhuang, Yuwen Wang, Shun Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Junlong Zhuang, Yuwen Wang, Shun Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
